LY.18 (ML40080, A17-190)
NCT04161248
LY18
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Status:
Opening Soon
I
Phase
2nd
Line of Therapy
Relapsed / Recurrent / Refractory
Disease Stage
Biomarker(s)
N/A
Investigational
Product
Venetoclax
Treatment Arms
o Experimental: Venetoclax + R-GDP